USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ARIDIS PHARMACEUTICALS, LLC
Address:
5941 Optical Court
San Jose, CA 95138-1400
Phone:
N/A
URL:
N/A
EIN:
132007450
DUNS:
141088463
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,140,738.00 3
STTR Phase I $543,629.00 1
STTR Phase II $2,922,383.00 1

Award List:

Live, oral, heat Stable S. typhi TY21a vaccine

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$974,606.00
Agency:
HHS
Principal Investigator:
Eric Patzer
Abstract:
DESCRIPTION (provided by applicant): Vaccines represent a proven and effective approach for assuring widespread protection of large populations and can be used to reduce the number of susceptible individuals prior to or immediately following a bioterrorism attack. This project addresses two… More

Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$543,629.00
Agency:
HHS
Principal Investigator:
Research Institution:
BRIGHAM AND WOMEN'S HOSPITAL
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Cystic Fibrosis (CF) is an autosomal recessive disorder, which leads to the abnormal composition and physical properties of airway secretions in CF patients. Additionally, the lungs of CF patients are particularly susce ptible to chronic bacterial infections with… More

Inhalable Gallium Nitrate Anti-Infective Powder for CF

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$599,829.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cystic Fibrosis (CF) is an autosomal recessive disorder, which leads to the abnormal composition and physical properties of airway secretions in CF patients. Additionally, the lungs of CF patients are particularly susce ptible to chronic bacterial infections with… More

Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis

Award Year / Program / Phase:
2011 / STTR / Phase II
Award Amount:
$2,922,383.00
Agency:
HHS
Principal Investigator:
Eric J. Patzer – 408-385-1742
Research Institution:
WAISMAN BIOMANUFACTURING FACILITY, UNIVERSITY OF WISCONSIN
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Over the past two decades, the number of new antimicrobials being developed has experienced a greater than 60% decline, while the number of antibiotic resistant microorganisms has been steadily increasing. Only one newantibacterial drug with a novel mechanism of… More

Stable Vaccines Delivered on Oral Thin Films

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$566,303.00
Agency:
HHS
Principal Investigator:
Vu L. Truong – 408-385-1742
Abstract:
DESCRIPTION (provided by applicant): Our goal is to develop a vaccine that is stable at ambient conditions, and to incorporate the vaccine into an effective dosage presentation that can facilitate storage, distribution, and mass vaccination campaigns. Thecurrent pharmaceutical manufacturing… More